186 related articles for article (PubMed ID: 32103589)
1. Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.
Avitabile M; Lasorsa VA; Cantalupo S; Cardinale A; Cimmino F; Montella A; Capasso D; Haupt R; Amoroso L; Garaventa A; Quattrone A; Corrias MV; Iolascon A; Capasso M
J Cell Mol Med; 2020 Apr; 24(7):4072-4081. PubMed ID: 32103589
[TBL] [Abstract][Full Text] [Related]
2. Association of PARP1 rs4653734, rs907187 and rs1136410 variants with breast cancer risk among Iranian women.
Ramezani S; Sharafshah A; Mirzanejad L; Hadavi M
Gene; 2019 Sep; 712():143954. PubMed ID: 31288058
[TBL] [Abstract][Full Text] [Related]
3. Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.
Zhao X; Li D; Huang D; Song H; Mei H; Fang E; Wang X; Yang F; Zheng L; Huang K; Tong Q
Mol Ther; 2018 Mar; 26(3):755-773. PubMed ID: 29398485
[TBL] [Abstract][Full Text] [Related]
4. Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Wang Y; Xia XB; Tang HZ; Cai JR; Shi XK; Ji HX; Yan XN; Xu T
Mutagenesis; 2021 Aug; 36(4):281-293. PubMed ID: 34132814
[TBL] [Abstract][Full Text] [Related]
5. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Tempka D; Tokarz P; Chmielewska K; Kluska M; Pietrzak J; Rygielska Ż; Virág L; Robaszkiewicz A
Redox Biol; 2018 May; 15():316-326. PubMed ID: 29306194
[TBL] [Abstract][Full Text] [Related]
7. Impact of interleukin-6 -174 G>C gene promoter polymorphism on neuroblastoma.
Totaro F; Cimmino F; Pignataro P; Acierno G; De Mariano M; Longo L; Tonini GP; Iolascon A; Capasso M
PLoS One; 2013; 8(10):e76810. PubMed ID: 24204677
[TBL] [Abstract][Full Text] [Related]
8. Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
Jin J; Robeson H; Fagan P; Orloff MS
PLoS One; 2020; 15(12):e0243509. PubMed ID: 33284833
[TBL] [Abstract][Full Text] [Related]
9. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression.
Pottier N; Cheok MH; Yang W; Assem M; Tracey L; Obenauer JC; Panetta JC; Relling MV; Evans WE
Hum Mol Genet; 2007 Oct; 16(19):2261-71. PubMed ID: 17616514
[TBL] [Abstract][Full Text] [Related]
10. PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.
Long W; Zhao W; Ning B; Huang J; Chu J; Li L; Ma Q; Xing C; Wang HY; Liu Q; Wang RF
J Mol Cell Biol; 2018 Apr; 10(2):147-160. PubMed ID: 29452418
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.
Jin Y; Wang H; Han W; Lu J; Chu P; Han S; Ni X; Ning B; Yu D; Guo Y
Tumour Biol; 2016 Mar; 37(3):3739-47. PubMed ID: 26468016
[TBL] [Abstract][Full Text] [Related]
12. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
[TBL] [Abstract][Full Text] [Related]
13. Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.
Tian YN; Chen HD; Tian CQ; Wang YQ; Miao ZH
Cell Death Dis; 2020 Jan; 11(1):71. PubMed ID: 31992690
[TBL] [Abstract][Full Text] [Related]
14. Interaction among susceptibility genotypes of PARP1 SNPs in thyroid carcinoma.
Bashir K; Sarwar R; Saeed S; Mahjabeen I; Kayani MA
PLoS One; 2018; 13(9):e0199007. PubMed ID: 30183716
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
16. Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.
Nogueira A; Assis J; Faustino I; Pereira D; Catarino R; Medeiros R
Biomarkers; 2017 Feb; 22(1):70-76. PubMed ID: 27323894
[TBL] [Abstract][Full Text] [Related]
17. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
18. PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Gotoh N; Minato Y; Saitoh T; Takahashi N; Kasamatsu T; Souma K; Oda T; Hoshino T; Sakura T; Ishizaki T; Shimizu H; Takizawa M; Yokohama A; Tsukamoto N; Handa H; Murakami H
Eur J Haematol; 2020 Jun; 104(6):526-537. PubMed ID: 32003046
[TBL] [Abstract][Full Text] [Related]
19. Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.
Murai J; Pommier Y
Cancer Res; 2019 May; 79(10):2460-2461. PubMed ID: 31092408
[TBL] [Abstract][Full Text] [Related]
20. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
